Your browser doesn't support javascript.
loading
Chemical and biological characterization of vaccine adjuvant QS-21 produced via plant cell culture.
Lv, Xiangmin; Martin, Jesse; Hoover, Heather; Joshi, Bishnu; Wilkens, Margaret; Ullisch, David A; Leibold, Thomas; Juchum, John S; Revadkar, Sanket; Kalinovska, Barbara; Keith, Justin; Truby, Adam; Liu, Gui; Sun, Elaine; Haserick, John; DeGnore, Jon; Conolly, Joseph; Hill, Adrian V S; Baldoni, John; Kensil, Charlotte; Levey, Dan; Spencer, Alexandra J; Gorr, Gilbert; Findeis, Mark; Tanne, Antoine.
  • Lv X; Agenus, Inc, Lexington MA, USA.
  • Martin J; Agenus, Inc, Lexington MA, USA.
  • Hoover H; Agenus, Inc, Lexington MA, USA.
  • Joshi B; Agenus, Inc, Lexington MA, USA.
  • Wilkens M; Agenus, Inc, Lexington MA, USA.
  • Ullisch DA; Phyton Biotech GmbH, Ahrensburg, Germany.
  • Leibold T; Phyton Biotech GmbH, Ahrensburg, Germany.
  • Juchum JS; Phyton Biotech LLC, 1503 Cliveden Avenue, Delta, BC V3M 6P7, Canada.
  • Revadkar S; Agenus, Inc, Lexington MA, USA.
  • Kalinovska B; Agenus, Inc, Lexington MA, USA.
  • Keith J; Agenus, Inc, Lexington MA, USA.
  • Truby A; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Liu G; SaponiQx, Lexington MA, USA.
  • Sun E; Agenus, Inc, Lexington MA, USA.
  • Haserick J; Agenus, Inc, Lexington MA, USA.
  • DeGnore J; Agenus, Inc, Lexington MA, USA.
  • Conolly J; Agenus, Inc, Lexington MA, USA.
  • Hill AVS; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Baldoni J; SaponiQx, Lexington MA, USA.
  • Kensil C; SaponiQx, Lexington MA, USA.
  • Levey D; Agenus, Inc, Lexington MA, USA.
  • Spencer AJ; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Gorr G; Hunter Medical Research Institute, School of Biomedical Sciences and Pharmacy, College of Health, Medicine & Wellbeing; Immune Health Program, New Lambton Heights, NSW, Australia.
  • Findeis M; Phyton Biotech GmbH, Ahrensburg, Germany.
  • Tanne A; Agenus, Inc, Lexington MA, USA.
iScience ; 27(3): 109006, 2024 Mar 15.
Article en En | MEDLINE | ID: mdl-38361610
ABSTRACT
Many vaccines, including those using recombinant antigen subunits, rely on adjuvant(s) to enhance the efficacy of the host immune responses. Among the few adjuvants clinically approved, QS-21, a saponin-based immunomodulatory molecule isolated from the tree bark of Quillaja saponaria (QS) is used in complex formulations in approved effective vaccines. High demand of the QS raw material as well as manufacturing scalability limitation has been barriers here. We report for the first-time successful plant cell culture production of QS-21 having structural, chemical, and biologic, properties similar to the bark extracted product. These data ensure QS-21 and related saponins are broadly available and accessible to drug developers.
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2024 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2024 Tipo del documento: Article